Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

BMC Cancer

Table 3 Summary of multiple myeloma patients

Patient	Age	Type	D-S stage	V^R	T^R	L^R	Number of treatment lines^a
11	>65	IgG-λ	IIIa	N.A.	N.A.	N.A.	naive
4	>65	IgG-κ	IIIa	N.A.	N.A.	N.A.	naive
8	<65	λ	IIIa	Y	N.A.	Y	4
15	>65	IgA-λ	IIIa	Y	N.A.	Y	2
3	<65	IgG-λ	IIIa	Y	Y	Y	4
16	>65	IgG-κ	IIIa	Y	Y	Y	6
14	<65	λ	IIIb	Y	Y	Y	3
6	<65	IgG-κ	IIIa	Y	N	N.A.	2
7	<65	λ	IIIb	N	Y	Y	3

D-S Stage: The Durie-Salmon staging system. V: bortezomib. T: thalidomide. L: lenalidomide. R: resistance or refractory. N.A.: Not Applicable. Type: paraproteins IgG or IgA, κ-light chains κ or λ-light chains λ
^aFor patients who received autologous stem cell transplantation (ASCT), a regimen of induction + ASCT+/−maintanence was counted as one treatment line. Naive: no past treatment

ISSN: 1471-2407